Codone Biotech to Present Data on its Suppressor-tRNA Platform in Disease Models with Nonsense Mutations (Premature Termination Codons)
April 17 2024 - 8:00AM
Business Wire
Codone Biotechnology, which develops transformative medicines
based on Suppressor-tRNAs for patients with severe diseases caused
by nonsense mutations (aka, Premature Termination Codons), will
present data on its lead tRNA candidates at the poster session for
Late Breaking Abstract of the 27th American Society of Gene &
Cell Therapy (ASGCT) Annual Meeting on Wednesday, May 8, 2024.
Mutations in over 4000 genes are known to be involved in human
diseases, and 11% of these mutations are nonsense mutations leading
to protein truncations. These diseases can be potentially treated
by Suppressor-tRNAs, which are novel tRNAs engineered at its
anti-codon and other positions to readthrough nonsense mutations in
disease-causing genes to rescue full-length protein production and
functions, regardless of disease, genes or locations of nonsense
mutations. A Suppressor-tRNA for one type of nonsense mutations has
the potential to treat all diseases caused by such mutations.
“tRNA is the critical link between mRNA and protein, and
engineering tRNA into a therapy opens up a new front of modifying
protein translation to treat diseases,” said Lingjie Kong, Ph.D.,
Co-founder. “Our proprietary tRNA candidates have been validated in
multiple disease models with nonsense mutations in vitro and in
vivo, and we continue to make exciting progress in optimizing
leading molecules packaged in AAV.”
“Suppressor-tRNAs have the unique potential to become universal
treatment for a broad range of diseases with nonsense mutations,
and we focus on diseases with major symptoms in target organs
including CNS and kidney,” said Dong Wei, Ph.D., Co-founder. “With
support from our Scientific Advisory Board and collaborators, we
are dedicated to advancing lead candidates into clinics in two
years, bringing hope to patients in need.”
Details of the presentation:
Title: Suppressor-tRNA Delayed Disease
Progression in an Alport Syndrome Mouse Model
Date: 12:00 PM, May 8, 2024, EDT
Session Name: Wednesday Posters:
Late-Breaking Abstracts
Late-Breaking Abstract Number: LBA-16
About Codone Biotechnology
Founded in 2022, Codone Biotechnology focuses on developing
transformative medicines based on suppressor-tRNAs for patients
with severe diseases caused by premature termination codons. The
Company has established proprietary platforms in suppressor-tRNA
screening and optimization as well as AAV delivery, for broad range
of indications in target organs including Central Nervous System,
kidney, heart and retina.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240415780199/en/
Dong Wei, Ph.D. weidong@codonetx.com www.codonebio.com